Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers

Bayer

Status and phase: Completed; Phase 3

Conditions: Contraception

Treatments: Drug: Mercilon; Drug: Yasmin 20

Study type: Interventional

Funder types: Industry

Identifiers

NCT00624130

91352

308020

Details and patient eligibility

About

The purpose of this study is to compare bleeding pattern of contraceptive Yasmin 20 to a marketed comparator.

Enrollment: 453 patients

Sex: Female

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy female volunteer aged 18-35,
• Smokers 18-30

Exclusion criteria

• Contraindications for using hormonal contraceptives

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

453 participants in 2 patient groups

Arm 1

Experimental group

Treatment:

Drug: Yasmin 20

Arm 2

Active Comparator group

Treatment:

Drug: Mercilon